Creatine’s Potential Beyond Muscle: New Review Explores Brain Health and Depression

The world of sports supplementation has long been dominated by the recognized prowess of creatine in enhancing strength and muscle performance. However, a burgeoning area of scientific inquiry is now probing whether this popular ergogenic aid holds untapped potential far beyond the athletic arena, specifically in the complex realm of mental health. A recent systematic review, meticulously published in the esteemed journal Brain Medicine, has cast a spotlight on the intriguing possibility that creatine may offer therapeutic benefits for depression by bolstering the brain’s crucial energy needs. While the findings present a glimmer of cautious optimism, they simultaneously underscore the vast landscape of the unknown, revealing a landscape of clinical trials with divergent outcomes, leaving researchers at an analytical crossroads rather than a definitive conclusion.

Unpacking the Evidence: A Deep Dive into Clinical Trials

Rather than initiating novel experimental protocols, the research team, spearheaded by Bassam Jeryous Fares, a distinguished scholar from the University of Ottawa, embarked on a comprehensive analysis of existing clinical research. This systematic review meticulously sifted through the available scientific literature, ultimately identifying six published reports that encompassed five randomized controlled trials. In these controlled settings, participants were administered either creatine or a placebo, with neither the participants nor the researchers privy to the allocation until the study’s conclusion, a crucial element in minimizing bias.

These pivotal studies were geographically dispersed, originating from research institutions in South Korea, the United States, Brazil, Israel, and India. Collectively, they initiated with a cohort of 238 participants. Of this group, 126 individuals were allocated to receive creatine supplementation, while 112 were assigned to the placebo arm. The average age of participants hovered around 36 years, with a notable predominance of female participants. Indeed, two of the enrolled studies specifically focused exclusively on women, a demographic characteristic that may hold significance in interpreting the results. The research efforts were primarily directed towards understanding creatine’s impact on major depressive disorder, with four trials specifically targeting this condition. One study, however, broadened its scope to include participants diagnosed with bipolar disorder who were concurrently experiencing a depressive episode. The inherent heterogeneity in the design and methodological approaches employed across these studies precluded a consolidated statistical analysis. Consequently, the research team opted for an individualistic evaluation of each study’s findings, a testament to their commitment to rigorous scientific scrutiny.

A Divided Picture: Mixed Results in Depression Studies

The exhaustive review of the clinical evidence painted a distinctly bifurcated picture, revealing a complex and nuanced relationship between creatine supplementation and depressive symptoms.

Promising Avenues:

Two of the five examined trials, both of which exclusively enrolled women diagnosed with major depressive disorder, yielded compelling evidence suggesting that creatine supplementation provided discernible additional benefits. In one particularly noteworthy study, participants who received five grams of creatine daily in conjunction with the established antidepressant escitalopram demonstrated significantly greater reductions in depressive symptoms after an eight-week treatment period compared to their counterparts who received escitalopram alongside a placebo. This observed improvement was substantial by conventional statistical metrics, registering a Cohen’s d of 1.13 on the widely recognized Hamilton Depression Rating Scale. Furthermore, a higher proportion of participants in the creatine-augmented group achieved clinical remission, a critical indicator of sustained recovery.

In another encouraging trial, creatine was administered in combination with cognitive behavioral therapy (CBT). The findings indicated that participants who incorporated creatine into their treatment regimen experienced a more pronounced reduction in depression symptoms, as measured by a standard assessment tool, than those who received CBT solely with a placebo. These results, while positive, highlight the potential for creatine to act as an adjunct therapy, augmenting the efficacy of existing treatment modalities.

The Counterpoint:

However, the narrative is not uniformly positive. The remaining three trials, in stark contrast, reported no statistically significant or clinically meaningful benefit from creatine supplementation. One study investigated the effects of both five and ten grams of creatine per day in individuals whose depression had proven refractory to conventional medication. This investigation concluded that neither dosage regimen led to an improvement in their depressive symptoms. Another study, focusing on adolescent girls, found no discernible advantage of creatine over a placebo, even when various dosages were explored. A third trial, which specifically involved individuals with bipolar disorder experiencing depressive episodes, also failed to demonstrate any positive impact of creatine on their mood state.

A Note on Safety: Potential for Hypomania and Mania

Beyond the efficacy data, the review also brought to light an important safety consideration. Two participants within the bipolar disorder study who were administered creatine experienced adverse events, manifesting as hypomania or mania. This observation strongly suggests that creatine’s physiological effects may be modulated by an individual’s underlying psychiatric condition, warranting careful consideration and monitoring in specific patient populations. This finding underscores the critical need for personalized treatment approaches and thorough risk-benefit assessments, particularly for individuals with pre-existing mood disorders.

The Biological Rationale: Creatine’s Neurological Underpinnings

The scientific rationale underpinning the hypothesis that creatine could influence depression is deeply rooted in the brain’s extraordinary and relentless energy demands. While creatine is most widely recognized for its pivotal role in facilitating the rapid regeneration of adenosine triphosphate (ATP) – the primary energy currency of cells – within muscle tissue, the brain also relies heavily on this energy system for optimal functioning. Previous research has identified alterations in brain creatine metabolism in individuals diagnosed with mood disorders, prompting scientific curiosity into whether disruptions in cellular energy production might, in fact, contribute to the pathogenesis of depression.

Furthermore, there is a compelling theoretical basis suggesting that creatine may exert influence over dopaminergic and serotonergic pathways. These neurotransmitters, dopamine and serotonin, are intrinsically linked to mood regulation and are the primary targets of a vast array of antidepressant medications. By potentially modulating these crucial neurochemical systems, creatine could, in theory, contribute to mood stabilization.

Despite these compelling theoretical connections, the authors of the review unequivocally emphasize that these associations remain largely speculative. The existing studies, while suggestive, primarily demonstrate correlations rather than establishing definitive causal links between altered creatine metabolism and the development of depression. It is crucial to acknowledge that depression is a multifactorial disorder influenced by a complex interplay of numerous biological pathways.

Bassam Jeryous Fares, the lead author of the review and a doctoral candidate in the Faculty of Medicine at the University of Ottawa, articulated this nuanced perspective with clarity: "The signal is interesting, but it is not a verdict. Two trials pointed one way and three pointed another. That is not the kind of evidence on which you change clinical practice. It is the kind that tells you the question is worth further exploration."

Nicholas Fabiano, the corresponding author of the review and a psychiatry resident at the University of Ottawa, echoed this sentiment, urging a measured approach: "Creatine appears to be a safe intervention. The adverse events we found were limited to mild gastrointestinal discomfort. We cannot yet reliably say that creatine helps with depressive symptoms or if the findings are generalizable to everyone."

The Imperative for Larger, More Robust Studies

The researchers are unequivocal in their assertion that the current body of evidence is far too limited to advocate for the routine use of creatine as a treatment for depression. The clinical trials reviewed, while valuable, were characterized by several limitations. They were, by and large, relatively small in sample size and included a disproportionately higher representation of women compared to men. Moreover, the quality of these studies exhibited considerable variability. While two studies were assessed as having a low risk of bias, the remaining three raised certain concerns, primarily pertaining to the methodology of participant assignment and the completeness of reported data. Consequently, the findings derived from these studies cannot be broadly generalized to the wider population.

In light of these limitations, the review authors strongly recommend the initiation of larger and more prolonged clinical trials. These future investigations should extend beyond the current eight-week treatment durations to better assess long-term efficacy and safety. Furthermore, researchers are encouraged to explore the co-administration of creatine with exercise interventions, recognizing the well-established benefits of physical activity for mental health. Another critical area for future research involves systematically investigating whether varying dosages of creatine yield differential outcomes, while simultaneously acknowledging that higher doses do not necessarily translate into enhanced benefits.

Intriguingly, preliminary findings from animal studies may offer further insights. Experiments conducted on rodents have indicated that creatine can influence depression-like behaviors differently in male and female subjects. This observation could potentially shed light on why the human studies that predominantly featured female participants yielded the most pronounced positive results.

For the foreseeable future, creatine remains an area of intense scientific interest and an intriguing possibility, rather than a scientifically validated treatment for depression. A supplement historically synonymous with the pursuit of physical prowess is now capturing the attention of researchers diligently seeking novel and effective avenues for addressing the global mental health crisis.

The comprehensive peer-reviewed research article, titled "Creatine as a treatment for depression," was officially published in Brain Medicine and has been accessible through Open Access since June 30, 2026. This publication marks a significant step in the ongoing scientific dialogue surrounding creatine’s potential role in neurological and psychological well-being.